Home > Insider Trading > Filing (0001062993-23-023100)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1267565	Collegium Pharmaceutical Inc	COLL	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1443841	Joseph Ciaffoni	C/O Collegium Pharmaceutical, Inc. 100 Technology Center Drive Stoughton MA 02072	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-12-21	4,357	$21.34	279,357	No	4	M	Direct
Common Stock	Disposition	2023-12-21	4,357	$30.38	275,000	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Purchase)	Disposition	2023-12-21	4,357	$0.00	4,357	$21.34

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
16,875		2030-02-05	No	4	M	Direct

Footnotes

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2023.
The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.13 to $30.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2021, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the Reporting Person's continued service with the Issuer.